Profile data is unavailable for this security.
About the company
Median Technologies SA is a France-based company that publishes software for the diagnosis and monitoring of cancer patients. The Company develops lesion management solutions (LMS) to objectively measure and track cancerous or suspicious lesions, distribute a standardized oncologic report and centralize the lesion information for multidisciplinary review. The LMS line includes such products as LMS-Lung, a clinical application for the detection, evaluation and follow-up of lesions identified in CT images covering the chest; LMS-Track, a clinical application for the follow-up of oncology patients; and LMS-Liver, a clinical application for the initial evaluation and the follow-up of liver metastases and any other lesions identified in CT images covering the liver. The Company operates one subsidiary, Median Technologies Inc, based in the United States.
- Revenue in EUR (TTM)23.31m
- Net income in EUR-21.99m
- Incorporated2002
- Employees211.00
- LocationMedian Technologies SALes Deux Arcs - Batiment B 1800Route des CretesVALBONNE 06560FranceFRA
- Phone+33 493333777
- Fax+33 492906599
- Websitehttps://mediantechnologies.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Implanet SA | 11.10m | -4.81m | 33.08m | 44.00 | -- | -- | -- | 2.98 | -0.038 | -0.038 | 0.0876 | -0.0108 | 0.7432 | 0.8618 | 5.06 | 253,379.00 | -32.23 | -37.85 | -176.46 | -98.02 | 52.11 | 58.59 | -43.36 | -68.07 | 0.2485 | -- | 1.29 | -- | 26.31 | 4.89 | 21.87 | -- | 25.84 | -- |
| Diagnostic Medical Systems SA | 46.77m | -1.67m | 37.58m | 140.00 | -- | 2.35 | 41.43 | 0.8035 | -0.069 | -0.069 | 2.05 | 0.6006 | 0.876 | 1.84 | 4.52 | 324,798.60 | -2.86 | -11.47 | -5.81 | -20.52 | 39.79 | 38.72 | -3.27 | -14.95 | 0.6154 | -0.5203 | 0.5811 | -- | 9.29 | 8.24 | 70.50 | -- | -- | -- |
| Theraclion SA | 1.90m | -5.25m | 38.64m | 33.00 | -- | -- | -- | 20.31 | -0.1127 | -0.1127 | 0.0408 | -0.0548 | 0.1479 | 0.3304 | 8.74 | 59,455.31 | -40.84 | -33.44 | -55.80 | -47.33 | 54.01 | 66.95 | -276.15 | -360.91 | 1.79 | -67.33 | 2.50 | -- | -54.44 | -21.49 | -56.66 | -- | -4.97 | -- |
| AbL Diagnostics SA | 5.45m | 463.37k | 49.96m | 20.00 | 107.71 | 7.20 | 41.48 | 9.17 | 0.0288 | 0.0288 | 0.3383 | 0.4308 | 0.4416 | -- | 1.60 | 286,763.20 | 3.76 | 3.59 | 5.34 | 5.29 | -- | -- | 8.50 | 8.20 | 2.91 | -- | 0.2788 | -- | -5.03 | -- | 424.60 | -- | -- | -- |
| Median Technologies SA | 23.31m | -21.99m | 157.71m | 211.00 | -- | -- | -- | 6.77 | -1.16 | -1.16 | 1.23 | -2.08 | 0.8894 | -12.98 | 3.92 | 96,717.84 | -83.91 | -60.70 | -- | -232.35 | 102.73 | 102.32 | -94.35 | -97.73 | 0.3543 | -26.56 | -- | -- | 3.25 | 20.72 | -9.83 | -- | 43.77 | -- |
| Guerbet SA | 809.67m | 7.74m | 174.70m | 2.91k | 34.00 | 0.463 | 2.48 | 0.2158 | 0.4064 | 0.4064 | 64.25 | 29.85 | 0.7865 | 0.546 | 4.90 | 278,715.70 | 0.4619 | 0.92 | 0.6055 | 1.20 | 78.03 | 76.51 | 0.5873 | 1.19 | 1.03 | 1.46 | 0.5172 | 64.79 | 7.05 | 0.5853 | -32.61 | -15.50 | -0.8569 | -- |
| Affluent Medical SAS | 4.12m | -14.74m | 225.12m | 76.00 | -- | 7.08 | -- | 54.67 | -0.3759 | -0.3759 | 0.1051 | 0.5365 | 0.0709 | -- | 0.9541 | 59,681.16 | -25.40 | -23.76 | -32.61 | -27.59 | 1.34 | -226.93 | -358.01 | -1,815.40 | -- | -924.30 | 0.5030 | -- | -- | -- | 5.84 | -- | -- | -- |
| Lumibird SA | 215.95m | 10.73m | 505.50m | 1.07k | 47.12 | 2.53 | 16.61 | 2.34 | 0.4775 | 0.4775 | 9.61 | 8.90 | 0.5077 | 0.9593 | 4.42 | 202,198.50 | 2.52 | 2.51 | 3.11 | 3.17 | 63.89 | 61.89 | 4.97 | 4.90 | 1.64 | 3.16 | 0.4583 | 0.00 | 1.75 | 13.34 | -20.08 | -8.38 | 15.27 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Herald Investment Management Ltd.as of 31 Dec 2024 | 519.99k | 1.42% |
| Aguja Capital GmbHas of 30 Sep 2025 | 500.00k | 1.36% |
| Apo Asset Management GmbHas of 30 Apr 2024 | 477.24k | 1.30% |
| OFI Invest Asset Management SAas of 30 Dec 2025 | 400.00k | 1.09% |
| Montpensier Arbevel SASas of 30 Jun 2025 | 312.74k | 0.85% |
| Groupama Asset Management SAas of 31 Jan 2025 | 168.84k | 0.46% |
| Alphajet Fair Investors SASas of 27 Jan 2026 | 115.00k | 0.31% |
| Pure Capital SAas of 30 Jun 2025 | 97.16k | 0.27% |
| HSBC Global Asset Management (France) SAas of 28 Nov 2025 | 71.64k | 0.20% |
| PEH Wertpapier AG (Germany)as of 30 Jun 2025 | 52.50k | 0.14% |
